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2. LIST OF ABBREVIATIONS 
A  - surface area 
Å  - ångström 
Adiss,n  - dissolved amount of a solute at the n-th segment of the  
   gastrointestinal tract 
ADMET - absorption, distribution, metabolism, excretion and toxicity 
ASD  - amorphous solid dispersion 
ATR-FTIR - attenuated total reflectance - Fourier transform infrared 
BCS  - Biopharmaceutical Classification System 
Bq  - becquerel 
C  - concentration 
°C  - degree Celsius 
Ca  - capillary number 
CD  - carvedilol 
CDER  - Center for Drug Evaluation and Research 
Cs  - saturation concentration 
Cs,n  - solubility of the compound at the particle surface at the n-th  
   segment of the gastrointestinal tract 
Cu  - copper 
D  - diffusion coefficient 
D10%  - the particle size at the intercept of the cumulative distribution curve 
and 10% 
D50%  - median diameter, or the particle size at the intercept of the  
cumulative distribution curve and 50% 
D90%  - the particle size at the intercept of the cumulative distribution curve  
and 90% 
Δr  - electron layer thickness, equals to 1.66 Å 
DSC  - differential scanning calorimetry 
η  - dynamic viscosity 
ECavitation - cavitation energy 
ECM  - extracellular matric 
ECrystal Packing - crystal packing energy 
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ESolvation - solvation energy 
f1  - difference factor 
f2  - similarity factor 
FCent  - centrifugal force 
FDA  - U.S. Food and Drug Administration 
FTIR  - Fourier transform infrared spectroscopy 
𝛾𝛾𝑠𝑠l  - solid-liquid interfacial tension 
g  - Gram 
GI  - gastro-intestinal 
GIT  - gastro-intestinal tract 
h  - thickness of the diffusion layer 
happ  - apparent diffusion layer thickness 
HPC  - hydroxypropyl cellulose 
kB  - Boltzmann constant, equals to 1.38x10-23 JK-1 
kV  - kilovolt 
λ  - wavelength 
logP  - logarithm of partition coefficient 
m  - mass 
M  - molar (molar concentration) 
Mw  - molecular weight 
mA  - milliamper 
MD  - model drug 
MPa  - megapascal 
µg  - microgram 
mg  - milligram 
min  - minute 
mJ  - millijoule 
ml  - millilitre 
mm  - millimetre 
N  - newton 
nA  - nanoamper 
ω  - angular velocity 
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o-Ps  - ortho-positronium 
𝜋𝜋  - pi, mathematical constant, approximately 3.14159 
PALS  - positron annihilation lifetime spectroscopy 
pH  - pondus hydrogenii 
pKa  - acid dissociation constant 
ps  - picosecond 
r  - radius 
R  - universal gas constant, equals to 8.314 JK-1mol-1 
𝜌𝜌  - volumetric mass density RH  - relative humidity rpm  - revolutions per minute Rt  - dissolution value of reference at t time s  - second 
S  - solubility 
S∞  - normal solubility of a material with a plane surface 
SEM  - scanning electron microscope 
Sr  -  solubility of a particle of r radius 
SS  - solid solution 
t  - time 
𝜏𝜏3  - ortho-positronium lifetime 
T  - temperature 
Tt  - dissolution value of test at t time 
U  - polymer jet exit speed 
v  - number of ions dissociating from the solute 
V  - volume of dissolution medium 
Vlumen,n - volume of the liquid presented in the n-th segment of the  
   gastrointestinal tract 
% v/v  - volume concentration 
% w/w  - mass fraction, percentage by mass 
XRD  - powder X-ray diffraction  
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3. INTRODUCTION 
Recent trends in pharmaceutical industry enforce the consideration of novel dosage forms 
in course of the development of pharmaceutically active ingredients. The phenomenon of 
the increasing demands for special therapeutic purposes and the expanding proportion of 
actives of undesirable physicochemical properties have been of the major concerns for 
pharmaceutical researchers. A widely accepted approach for classifying pharmaceuticals 
is the biopharmaceutical drug classification system (BCS) in which actives are 
categorized based on their solubility and permeability is represented in Fig. 1 (Amidon et 
al., 1995). 
 
Figure 1 Illustration of Biopharmaceutical Classification System including typical 
representatives of each class 
 
As can be seen from Fig. 1, members of class I possess the most advantageous 
physicochemical features enabling their rapid and complete dissolution and absorption.  
The general view is that formulation is an effective way to improve the gastrointestinal 
behavior of drugs belonging to class II, while chemical modification should be considered 
for actives of classes III and IV (Pouton, 2006). A remarkable part of these formulations 
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focuses on the dissolution and solubility enhancement of the incorporated ingredients. 
However, it can be noted that several research papers were published turning the spotlight 
on the permeation and bioavailability improvement of drugs of class III and IV 
(Kaukonen et al., 2007; Özdemir et al., 2000; Sinha et al., 2010; Yu et al., 1999). 
Moreover, the assessment of class II drugs is further complicated since it has been 
demonstrated that an enhanced in vitro dissolution does not result necessarily in an 
increased oral bioavailability (Sarnes et al., 2014). Another crucial obstacle is that 
formulations usually cannot address such phenomenon as high rate of metabolism or 
extensive efflux transport associated with class II-IV drugs (Wu and Benet, 2005). 
The real problem lies in the ever-decreasing number of approvals of new chemical 
entities, which is partly believed as a consequence of the extensive proportion of drugs of 
unfavorable physicochemical features (Fig. 2). 
 
 
Figure 2 Number of original drug approvals per year by FDA (FDA, 2016) 
 
The root of this tendency lies in the regnant approaches in modern drug development: the 
rational drug discovery and the high throughput screening lead to poorer permeability and 
poorer solubility, respectively (Lipinski, 2000). Hann et al. have identified this issue as 
the aftermath of the upset balance between potency and ADMET features resulting in 
molecular obesity. This term refers to the large molecular size and lipophilicity, as well 
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as the poor aqueous solubility of the actives (Hann, 2011; Hann and Keseru, 2012). 
Against this background, it is not surprising that approximately 70% of new chemical 
entities and 30% of marketed drugs belong to the BCS class II (Wu and Kesisoglou, 
2010). The reason why the proportion of BCS class II drugs is smaller among marketed 
drugs is that such molecules had been neglected during the early development stages. 
 
3.1. Solubility and the rate of dissolution 
In physical chemistry, two kinds of solubilities can be distinguished: the thermodynamic 
solubility and the kinetic solubility. The thermodynamic solubility refers to a physically 
long-term stable condition, and can be described as the concentration of a solute in a 
solution in equilibrium with the normal sized powder of the most stable crystalline state. 
The kinetic solubility is not a physically long-term stable condition and is defined as the 
concentration of a solute in a solution in equilibrium with a metastable crystalline state. 
The kinetic solubility is usually higher than thermodynamic solubility (Janssens and Van 
den Mooter, 2009; Mauludin et al., 2009).  
Generally, three quantities have been recognized, which affect the solubility (S) of a drug, 
and their relationship with solubility is described in the following equation: 
 
𝑆𝑆 = 𝑓𝑓(𝐸𝐸𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑃𝑃𝐶𝐶𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 + 𝐸𝐸𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃 + 𝐸𝐸𝑆𝑆𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃)  (1) 
 
where ECrystal Packing refers to the endoergic energy responsible for the disruption of the 
crystalline lattice in order to remove molecules from. ECavitation means the endoergic 
energy related to the disruption of the water molecules creating a cavity suitable to host 
the solute, and ESolvation represents the resultant energy deriving from the interactions of 
the solute and the solvent (Lipinski et al., 2012). 
The applied solvent, solvent mixture, the temperature, pH, solid state, ionic strength are 
the main parameters affecting the solubility of a given compound (Stegemann et al., 
2007). 
Another important characteristic of the drug liberation is the rate of dissolution, which is 
equivalent to the amount of drug dissolved per unit time. Noyes and Whitney described 
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the proportionality between the dissolution rate and the difference of the concentration of 
the saturated solution and the solution in question (Noyes and Whitney, 1897). 
Later on, Nernst and Brunner published an improved equation (Eq. (2)) on the basis of 
the diffusion layer approach: 
 
𝑑𝑑𝐶𝐶
𝑑𝑑𝐶𝐶
= 𝐷𝐷𝐷𝐷
𝑉𝑉ℎ
(𝐶𝐶𝑆𝑆 − 𝐶𝐶)         (2) 
 
where D is the diffusion coefficient, A the surface area of the interface between the 
compound to be solved and the solution, V the volume of the dissolution medium, h the 
thickness of the diffusion layer, CS the saturation solubility and C the concentration of the 
solute in the bulk phase at t time (Brunner, 1904; Dokoumetzidis and Macheras, 2006; 
Nernst, 1904). 
Regarding the huge number of research papers focusing on particle size reduction and the 
formulation of nanoscale drug delivery systems it is essential to discuss the impact of 
particle size and interfacial tension on the solubility. The dependence of the saturation 
solubility on the particle size was given by Ostwald and Freundlich (Eq. (3)):  
 
𝜌𝜌𝜌𝜌
𝑅𝑅𝑅𝑅
𝑀𝑀𝑤𝑤
𝑙𝑙𝑙𝑙
𝑆𝑆𝑟𝑟
𝑆𝑆∞
= 2𝛾𝛾𝑠𝑠𝑠𝑠
𝐶𝐶
         (3) 
 
where ρ is the volumetric mass density, r the radius of the particles, v represents the 
number of ions dissociating from the solute, M the molecular weight of the solute, γsl the 
solid-liquid interfacial tension, R the ideal gas constant, T the temperature Sr and S∞ the 
solubility of the particle of r radius and the normal solubility of a plane surface, 
respectively (Wu and Nancollas, 1998). In other words, the solubility of a compound of 
a given particle size changes exponentially with the reciprocal radius. However, it must 
be noted that the particle size reduction related solubility enhancement is significant only 
below a particle size of 2 µm and even more below 1 µm (Müller et al., 2000). 
Since Eqs. 2 and 3 are applicable only in the existence of a steady state condition 
suggesting a linear concentration gradient along with the diffusion layer, Wang and 
Flanagan introduced a new equation taking into account that the dissolution rate is 
influenced by the surface curvature and that the width of apparent diffusion layer alters 
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with change of the particle size. The authors proposed that in case of monodispersed 
spherical particles, h in Eq. (2) should be replaced with happ, the apparent diffusion layer 
thickness, which was given as 
 
1
ℎ𝑎𝑎𝑎𝑎𝑎𝑎
= 1
ℎ
+ 1
𝐶𝐶
         (4) 
where h is the diffusion layer thickness, and r the particle radius (Wang and Flanagan, 
1999, 2002). 
Based on these considerations, to describe in vivo conditions, the following equation (Eq. 
(5)) can be defined: 
 
𝑑𝑑𝐷𝐷𝑑𝑑𝑑𝑑𝑠𝑠𝑠𝑠,𝑛𝑛
𝑑𝑑𝐶𝐶
= −4𝜋𝜋𝑟𝑟2(𝑡𝑡)𝐷𝐷 � 1
𝐶𝐶(𝐶𝐶) + 1ℎ� �𝐶𝐶𝐶𝐶,𝑃𝑃 − 𝐷𝐷𝑑𝑑𝑑𝑑𝑠𝑠𝑠𝑠,𝑛𝑛𝑉𝑉𝑠𝑠𝑙𝑙𝑙𝑙𝑙𝑙𝑛𝑛,𝑛𝑛(𝐶𝐶)�  (5) 
 
where, dAdiss,n/dt is the dissolution rate of the particle of r(t) radius at t time, D the 
diffusion coefficient, h the diffusion layer thickness, Cs,n the compound solubility at the 
partice surface, Adiss,n the dissolved amount of the solute, and Vlumen the volume of the 
liquid presented in the n-th segment of the gastrointestinal tract (GIT) (Jamei et al., 2009). 
3.1.1. The biopharmaceutical aspects of solubility 
Though there are some exceptions (active or the paracellular transport), the vast majority 
of the active ingredients is absorbed from the GIT via passive diffusion (Bravo-Osuna et 
al., 2008). The generally accepted model for the gastrointestinal absorption of these drugs 
requires for dissolved active compound at the absorption sites (Jamei et al., 2009; Rao et 
al., 2009; van De Waterbeemd et al., 2001). Two main scenario can be classified on this 
basis. One is that when the drug remains undissolved at the window of absorption because 
of its poor solubility. The other is that when the rate of dissolution is too low, therefore 
the transit time is not sufficient for the complete dissolution and solid drug particles pass 
through the absorption site (Hörter and Dressman, 2001). 
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Figure 3 The relationship of poor solubility and the ADME scheme (Leach et al., 2006; 
Merisko-Liversidge and Liversidge, 2011; Wu and Benet, 2005)  
 
The most pronounced effect of inadequate solubility features is the low bioavailability. 
Alongside with the absorption issue, difficulties of the lead optimization and dosing are 
not negligible, as well. Furthermore, such active compounds often call for innovative 
dosage forms comprising excipients which are not indifferent to the human body. 
Additionally, these approaches often try to ameliorate poor solubility properties by the 
kinetic solubility using a dosage form containing drugs in a metastable state (e.g. 
amorphous state). Since the kinetic solubility is not a long-term stable condition and 
uncontrollable precipitation can occur, large variabilities of bioavailability can be 
expected. Parenteral and other dosage forms associated with discomfort and complication 
at administration can result in a diminished patients’ compliance (Kayser et al., 2003; 
Merisko-Liversidge and Liversidge, 2011). With respect to acidic compounds, the 
formulation of an immediate release dosage forms can be arduous because of the 
dissolution hampering and precipitation facilitating effect of the acidic media in the upper 
tracts of the GIT (Maggi et al., 2015). 
Fig. 3 illustrates how poor aqueous solubility influences the fate of drugs in the human 
body (Leach et al., 2006; Merisko-Liversidge and Liversidge, 2011; Wu and Benet, 
2005). 
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Finally, it is important to emphasize the significance of the proper physicochemical and 
biological characterization of the actives. This is especially interesting for drugs, where 
low oral exposure is attributed to the poor aqueous solubility, whilst intensive efflux or 
presystemic metabolic activity are behind the phenomenon, thus low solubility veils poor 
permeability feature (Stella and Nti-Addae, 2007).  Cyclosporine represents a typical 
example, where formerly the low oral performance was assigned to its poor aqueous 
solubility and high lipophilicity. Further investigations revealed that the real extent of 
absorption exceeds much more the presumed value and indicated that the observed low 
oral bioavailability is a consequence of the intestinal metabolism (Benet et al., 1996; 
Hebert et al., 1992; Wu et al., 1995).  
3.2. Pharmaceutical strategies to overcome poor solubility in solid dosage forms 
 
Figure 4 Structural differences of the main approaches for the dissolution enhancement 
of poorly soluble drugs: a) particle size reduction, b) amorphous drug dispersion c) solid 
solutions 
 
Apart from chemical approaches, e.g. pH adjustment, salt formation, complexation or the 
prodrug strategy, the most important means of overcoming the solubility issue are still 
resting on the basis of physical principles. Therefore this chapter focuses on approaches 
based on physical methods for improving solubility. 
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As can be seen in Fig. 4, the three major approaches of such efforts are the particle size 
reduction, the formation of amorphous dispersions and solid solutions. 
3.2.1. Particle size reduction 
Particle size reduction is a long-standing way of handling poorly soluble drugs. Lowering 
particle radius influences diffusion coefficient, lessens diffusion layer thickness (Eq. (4)) 
and increases concentration gradient, thus manifesting as an increment of dissolution rate 
and as the improvement of solubility, as well. The lower the particle radius the larger the 
diffusion coefficient according to Eq. (6) known as the Stokes-Einstein relationship: 
 
𝐷𝐷 = 𝑃𝑃𝐵𝐵𝑅𝑅
6𝜋𝜋𝜋𝜋𝐶𝐶
          (6) 
 
where r is the radius of the spherical particle, kB is Boltzmann’s constant, T is the 
temperature and η is the dynamic viscosity of the solution (Edward, 1970). Based on Eq. 
(2) it is easy to see that dissolution rate is directly proportional to the particle size 
dependent diffusion coefficient.  
In case of an appropriate extent of size reduction, i.e. particle radius below 1 µm, the 
solubility surplus can reach such degree, which allows the formulation of poorly soluble 
compounds (Eq. (3)).  
There are a great number of particle size reducing methods, which can be classified in 
two groups, the bottom up and the top down techniques. In the instance of bottom up 
approaches, fine particles are obtained from a homogenous system (usually solutions) 
exposed to a physical or chemical trigger. The latter refers to techniques, which scale 
down particle radius by means of mechanical or other physical energy. The conventional 
methods for particle size reduction are listed in Table 1. 
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Table 1 Overview of the particle size reducing techniques 
 Benefits Drawbacks Reference 
Top Down Methods 
Milling basic and easy 
technology, 
time-saving, 
solvent free 
 
physical and 
thermal stress 
can induce drug 
degradation, 
erosion from 
milling pearls 
 
(Keck and 
Müller, 2006; 
Savjani et al., 
2012) 
High pressure 
homogenization 
simple, time-
saving, solvent 
free 
multiple cycles 
required for 
desired particle 
size, small 
sample particles 
needed 
(Chen et al., 
2011; Hecq et 
al., 2005; Keck 
and Müller, 
2006; Patravale 
et al., 2004) 
Bottom up techniques 
Precipitation/Crystallization simple, low cost uncontrollable 
crystal growth 
during 
precipitation, 
drug must be 
soluble at least in 
one solvent,  
rapid crystal 
growth can result 
in crystal 
imperfection and 
inclusion of 
impurities 
(Müller et al., 
2000; Rabinow, 
2004) 
Spray drying narrow size 
distribution, 
thermal stress, 
drug should be 
(Broadhead et 
al., 1992; Liu et 
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yields spherical 
particles, 
one-step method 
soluble at least in 
one solvent, 
costs of the 
method 
al., 2015b; Patel 
et al., 2015) 
 
The term micronization refers to procedures in which particle size is reduced to a few 
micrometers, usually to 1-10 µm (Bansal et al., 2011). Micronization itself facilitates drug 
dissolution, but it is not considered as a suitable way for solubility enhancement. 
Therefore much more interest has been given to the preparation of nanosized particles or 
nanosuspensions. 
One of the major drawbacks of particle size reduction arises from the increase of surface 
area and of surface energy resulting in a greater tendency to agglomerate. Thus the control 
of surface particles can be vital. Moreover, crystal imperfections, and formation of 
amorphous regions can decrease stability, as well (Shoyele and Cawthorne, 2006). On the 
other hand, declined flow properties and wettability may constitute barriers to further 
processing, e.g. tableting (Karavas et al., 2006). 
3.2.2. Amorphous solid dispersions 
Preparation of amorphous solid drug dispersions (ASDs) offers a promising means of 
increasing solubility. ASDs are multicomponent systems comprising an amorphous active 
ingredient in a carrier, that is usually a polymer (Newman et al., 2015). In ASDs, the 
active ingredient forms amorphous clusters in the carrier (Fig. 4). The principle of this 
method is the circumvention of low thermodynamic aqueous solubility by means of 
development of a solid system containing poorly soluble drug in a metastable state 
possessing an apparent solubility greater than that of the initial drug. ASDs are often 
referred to as spring-parachute systems. By virtue of their high chemical potential, drugs 
incorporated in ASDs are spouted in the dissolution fluid resembling a compressed 
spring. However, this higher energy form of the drug tends to precipitate, but the applied 
excipients act like a parachutes by hindering precipitation (Guzmán et al., 2007) . 
It is considered that the decisive energy among three quantities given in Eq. (1) is ECrystal 
Packing, that is greater than the other two values. For this reason any efforts done to decrease 
ECrystal Packing engenders in a notable solubility improvement (Brough and Williams Iii, 
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2013; Lipinski et al., 2012). Basically, in the course of getting contact with 
gastrointestinal fluids, ASD releases its active ingredient forming a thermodynamically 
unstable supersaturated solution (a solution in which a solute has a concentration greater 
than its equilibrium concentration) (Brouwers et al., 2009). 
Because of their numerous benefits, such as enhanced wettability, higher porosity and 
increased specific surface area, ASDs have gained particular interest in new formulation 
strategies (Karavas et al., 2006). As a result of the presence of the polymeric matrix, 
ASDs exhibit better physicochemical stability than neat amorphous actives themselves. 
This can be attributed to the decreased molecular mobility originating from drug-
excipient interactions (Taylor and Zografi, 1997; Yoshioka et al., 1994; Zhou et al., 
2007). Molecular mobility has an impact on phase separation and drug recrystallization, 
therefore it is crucial from the point of stability (Janssens and Van den Mooter, 2009). 
Formation of strong drug-polymer interactions (ionic interactions and hydrogen bonds) 
and polymer-drug miscibility are of special impact for the physical stability (Li et al., 
2014; Tian et al., 2014). In addition, polymers and surfactants hamper drug 
recrystallization during dissolution through the solubilization of the active. Another 
important aspect of ASDs relates to the wide range of polymers enabling the achievement 
of modified release. 
On the contrary, the miscibility of the active and polymer is limited, therefore high weight 
fraction of the drug can lead to phase separation (Qi et al., 2010; Six et al., 2002; Six et 
al., 2004). Thus along with poor physical stability, the limited drug loading capacity can 
be considered one of the major disadvantages of this approach. 
Preparation of ASDs can be carried out using a solvent, a melting or a solvent-melting 
method, as well (Brough and Williams Iii, 2013; Squillante and Sethia, 2003). Solvent 
methods are based on the evaporation of a solvent from the solution of the drug and the 
polymer. Melting techniques require for the heating of the drug-excipient mixture above 
its glass transition temperature, and then for a cooling step with due regard to avoid 
recrystallization.  The most frequently applied methods are listed in Table 2. 
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Table 2 Overview of the solvent and melting techniques 
Method Advantages Disadvantages References 
Melting methods 
Hot-melt  
extrusion 
modified release, reduced 
number of processing 
steps, 
uniform drug distribution, 
continuous process, 
high throughput rate, 
solvent-free 
 
thermals stress, 
recrystallization 
upon cooling, 
high energy input, 
shear forces 
(Breitenbach, 2002; 
Crowley et al., 
2007; Repka et al., 
2007) 
Injection  
molding 
solvent-free, continuous 
process, rapid technique, 
scalability and 
patentability, possibility of 
autosterilization 
high pressure, 
high temperature 
(Konig et al., 1997; 
Zema et al., 2012) 
Solvent methods 
Spray drying narrow size distribution, 
yields spherical particles, 
one-step method, 
thermal stress, 
drug should be 
soluble at least in 
one solvent, 
costly, toxicity of 
organic solvents 
(Broadhead et al., 
1992; Liu et al., 
2015b; Patel et al., 
2015; Weuts et al., 
2004) 
Lyophilisation aqueous and organic 
solutions, high porosity,  
costly, requires a 
great amount of 
water to dissolve 
poorly soluble 
drug, toxicity of 
organic solvents 
(Ahmed et al., 
2006; El-Badry and 
Fathy, 2006; Oetjen 
and Haseley, 2007) 
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3.2.3. Solid solutions 
Solid solutions (SSs) are solutions comprising a solid solute in a solid solvent, hence the 
solute is molecularly dispersed resulting in the formation of a homogenous amorphous 
phase (Fig. 4). Glass solutions should be also noted here, where a solid is dissolved in 
glassy system, but in the relevant literature there is no consensus for the differentiation of 
these terms, they are often referred as synonyms (Chiou and Riegelman, 1971; Patterson 
et al., 2007). In general, the formulation of SSs result in a transparent system, while ASDs 
are usually opaque. It is not an effortless attempt to uncover the differences by using 
traditional physicochemical methods, e.g. differential scanning calorimetry (DSC), 
powder X-ray diffraction, Raman spectroscopy or Fourier transform infrared 
spectroscopy (FTIR), since the results of such measurements usually do not indicate the 
nature of the system. Nevertheless, modern techniques, such as solid-state nuclear 
magnetic resonance provide opportunity to gain information about the nature of the 
dispersion characteristics of the drug (Djuric et al., 2010; Ito et al., 2010; Pham et al., 
2010; Stejskal et al., 1981). 
The theoretical background of the solubility and dissolution enhancement effect of SSs is 
the same as expounded in the previous section above. The main difference lies in the 
distribution of the incorporated drug. By reason of the molecular dispersion, SSs represent 
the pinnacle of the amorphous formulations, since this approach takes advantage of 
particle size reduction and amorphous conversion as much as possible. In view of reduced 
molecular mobility and molecular dispersity, the statistical probability of encounter of 
drug molecules to form crystals is much lower than in other systems. 
Basically, all of the techniques listed in Table 2 are capable for the formulation of SSs 
suggesting that the formation of SSs or ASDs depends on the applied excipients and 
process parameters rather than the chosen method. It has been found that the development 
of strong drug-excipient interaction plays a pivotal role from the point of the formation 
of SSs (Aldén et al., 1993). On the other hand ensuring good miscibility is also essential 
(Andrews et al., 2010). 
Polymeric micro- and nanofibers represent unique carrier systems, that are also capable 
for the formulation of SSs and they are discussed in details in the next section. 
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3.3. Polymeric micro- and nanofibers in the pharmaceutical research 
Even though, naturally occurring fibrous systems have been long present in the human 
history (such as cobweb, plant fibers or musculoskeletal tissues) the consideration of 
these structures as potential drug delivery systems is quite a new concept. Nowadays, the 
role of polymeric fibers in the formulation development of special dosage forms is 
unquestionable, which is well supported by the growing interest for these systems. Fig. 5 
strikingly demonstrating that over the past 20 years the number of documents published 
concerning this topic have been sharply increased.  
 
 
Figure 5 Number of published documents per year based extracted from Scopus search 
results analysis using the following keywords: fiber, drug delivery system 
3.3.1. Structure and physicochemical features of polymeric fibers 
Polymeric fibers owe their popularity to their unique physicochemical characteristics, 
which are well exploitable for the formulation of innovative drug delivery systems.  
Because of their fibrous nature and small diameter, they can be characterized with high 
specific area-to-volume ratio (Tennent et al., 2000; Zhang et al., 2005b). High specific 
area-to-volume ratio is beneficial from the point of dissolution, since larger the surface 
area, the faster the drug dissolution, according to Eq. (2). High porosity and the possibility 
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to keep drugs in amorphous state are also a favorable properties for dissolution 
enhancement and for biological applications (Frenot and Chronakis, 2003; Szabó and 
Zelkó, 2015).  
Since the structure of these fibers resembles to the extracellular matrix (ECM), these are 
potential candidates for tissue engineering applications. ECM has an important role in the 
regulation and maintenance of biologic function of living tissues through providing 
mechanical support and through the mediation of biological signals (Hay, 2013; Reddi, 
2000). Fibrous scaffolds serve as an interim ECM until the regeneration and the formation 
of a native ECM.  
 
 
Figure 6 Basic types of polymeric microfibers, a: blend type, b-d: core-shell type, e: 
immobilized, f: hollow fibers 
 
Furthermore, the availability of natural polymers, such as collagen makes these systems 
even more attractive for biological applications, since the more perfectly is the 
mimicking, the better repairing efficacy can be achieved (Pham et al., 2006). 
As can be seen from Fig. 6, different types of fibers can be classified based on the 
distribution of the drug and the applied polymers. 
Blend or matrix type fibers represent a simple structure consisting a drug uniformly 
dispersed in a carrier matrix. Immobilized fibers comprise a neat carrier and a drug 
attached to its surface by chemical or intermolecular bonds. Core-shell fibers are built up 
of two coaxial matrices, the drug can be incorporated in various arrangements as 
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illustrated in Fig. 6. Furthermore, the inner part of the fiber can consist of drug only. For 
the time being, hollow fibers have meager pharmaceutical importance (Li et al., 2005). 
The fiber structure offers an opportunity to tailor release properties. While in case of blend 
type fibers, the drug release depends on the hydrophilicity of the chosen polymer, in case 
of core-shell type fibers sustained release, and biphasic release can be also achieved 
(Jiang et al., 2012; Szabó and Zelkó, 2015; Yu et al., 2013). 
Surface properties play a critical role in drug delivery and biological applications. 
Biocompatibility is usually a desired property, while biodegradability can be a supportive 
feature in certain cases (Pelipenko et al., 2015). Beyond hydrophilicity or hydrophobicity, 
more broadly, surface properties cover the surface functionalization of fibers, too. Surface 
functionalization is the chemical modification or the coating of fibers (Fang et al., 2008). 
Changing the chemical environment on the surface of fibers offers a tool for adjusting 
release properties, drug loading and surface hydrophobicity (Jacobs et al., 2011; Xie et 
al., 2012). For instance, developing ionic groups allows the formation of ionic 
interactions (Jiang et al., 2014). Coating of fibers can aim at the preparation of stimuli-
responsive drug delivery systems, such as pH-dependent drug dissolution or other release 
modifying purposes, e.g. reducing burst release (Jiang et al., 2014; Risdian et al., 2015; 
Zeng et al., 2005a). 
It has been demonstrated, that during the fiber formation, a supramolecular ordered 
structure can be developed (Cui et al., 2006; Sebe et al., 2013). The exact role of this kind 
of ordering in the function of fiber based formulations have been not revealed yet. But it 
can be proposed that this has an impact on molecular mobility and drug-excipient 
interactions, thus the stability of such formulations. 
3.3.2. Polymers for fiber formation 
Since the dawn of modern pharmaceutical development and manufacturing, polymers 
have received a particular attention, and this is no different for both micro- and 
nanofibers, where most of the relevant papers focuses on the formulation of polymeric 
based fibers. Accordingly, scientific publications cover the whole spectrum of polymers 
available. Basically, natural, semisynthetic and synthetic polymers are equally frequently 
used (Table 3). 
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Table 3 Polymers frequently applied in fiber formation classified by their origin 
Source of polymer Representative Reference 
Natural sodium alginate (Bonino et al., 2011; Jeong 
et al., 2010; Nie et al., 
2008) 
 collagen (Dong et al., 2009; Liu et 
al., 2010; Rho et al., 2006; 
Song et al., 2008) 
 hyaluronic acid (Ji et al., 2006; Li et al., 
2006; Liu et al., 2011; Um 
et al., 2004) 
 nucleic acids (Fang and Reneker, 1997; 
Kim and Yoo, 2010; Liu et 
al., 2007) 
 cellulose (Kim et al., 2006; Kim et 
al., 2005; Xu et al., 2008) 
Semisynthetic chitosan (Bhattarai et al., 2005; 
Geng et al., 2005; Ohkawa 
et al., 2004) 
 hydroxypropyl cellulose (Shukla et al., 2005; Szabó 
et al., 2014a; Szabó et al., 
2014b; Szabó et al., 2015) 
Synthethic poly(vinylpyrrolidone) (Adeli, 2015; Sebe et al., 
2014; Sebe et al., 2015; 
Sebe et al., 2013; Vigh et 
al., 2013) 
 poly(vinyl alcohol) (Kenawy et al., 2007; 
Taepaiboon et al., 2006; 
Zhang et al., 2005a) 
 poly(lactic acid) (Liu et al., 2015a; Monnier 
et al., 2015; Sonseca et al., 
2012; Xu et al., 2006) 
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 poly(glycolic acid) (Boland et al., 2001; Dong 
et al., 2008; Hajiali et al., 
2011) 
  poly(lactic-co-glycolic 
acid) 
(Xie and Wang, 2006; You 
et al., 2006) 
 
The paramount functionality-related characteristics of the polymers are the solubility, 
wetting properties, biodegradability and biocompatibility.  
Solubility of the polymer plays a decisive role during the formulation, because the 
solubility of the chosen polymer has a great impact on the release kinetics of the active 
substance. Generally, the use of water soluble, hydrophilic polymers results in a rapid, 
immediate drug release, while hydrophobic or swelling polymers could be exploited in 
controlled release formulations (Szabó and Zelkó, 2015). So-called release modifying 
agents are low molecular weight hydrophilic polymers or surfactants (e.g. poly(ethylene 
glycol)), which can enhance surface hydrophilicity, thus facilitating the proper drug 
dissolution (Maretschek et al., 2008; Puhl et al., 2014). Biodegradability, i.e. the 
hydrolytic or enzymatic degradation of the carrier is relevant in terms of erosion 
controlled drug delivery systems, as well as biological applications, where the role of 
fabricated fibrous scaffold will be replaced by the continuous generation of the ECM. The 
relevance of biocompatibility is mainly pronounced in biological applications, where the 
interaction of the living tissues and their constitutive cells is a key element of the 
biological effect. 
3.3.3. Fiber formation techniques 
In the scientific literature several methods are known for fiber formation, however the 
vast majority of the publications focuses on only a couple of techniques. Classification of 
these methods can be performed considering various aspects, such as the nature of the 
sample or the driving force of the fiber formation. Thus we can distinguish physical and 
chemical methods, but it should be noted that the former is much more dominant. The 
driving force of the physical fiber formation can be solvent evaporation or cooling 
supported by electrostatic, pneumatic or centrifugal forces. Table 4 summarizes the 
available methods for fiber preparation. The table also highlights the versatility of 
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electrospinning, forcespinning and blowspinning, since these techniques can handle 
either solutions or melts; hence these are the most favorable choices for pharmaceutical 
purposes. Furthermore, electrospinning process can be facilitated with air blowing 
(Nayak et al., 2011). 
 
Table 4 Fiber formation techniques (Nayak et al., 2011) 
Fiber formation method 
Chemical methods Physical methods 
 Solvent based methods Melt methods 
interfacial polymerization electrospinning electrospinning 
template synthesis forcespinning forcespinning 
self-assembly solution-blow spinning melt-blow spinning 
 drawing template melt extrusion 
 phase separation  
3.3.3.1. Electrospinning 
Because of its easy configuration, versatility and scalability, electrospinning has emerged 
as the most popular technique for fiber formation. This technique provides a great control 
over product characteristics and enables the preparation of almost every kind of fiber 
structures. The principle of electrospinning is epitomized in Figure 7. This method 
requires for a viscoelastic sample; a solution or melt, which is put in a syringe with a 
needle on it and then it is exposed to a high voltage. When the applied voltage is large 
enough to overcome the surface tension, polymeric jets will be ejected. In more detail, 
the high voltage upsets the equilibrium between surface tension and electric field 
potential, which stabilizes the shape of a droplet. This disturbance leads to the conical 
deformation of the droplet developing the so-called Taylor cone (Fig. 7). The unstable 
state results in the fission of Taylor cone, thus jet formation can take place (Yarin et al., 
2001).  The formed electrostatic field also expedite fiber production by accelerating and 
stretching jets towards the collector. The solidification of the ejected jets by the 
evaporation of solvent or cooling enables the formation of solid fibers (Pham et al., 2006; 
Teo and Ramakrishna, 2006). Finally, fibers are caught on the surface of the grounded 
collector. Electrospinning produces continuous fibers of a diameter ranging from a few 
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nanometers to a few micrometers. Hitherto, more than 200 polymers have been reported 
to be suitable for electrospinning remarkably indicating its significance (Bhardwaj and 
Kundu, 2010).  
 
Figure 7 A schematic representation of a typical electrospinning arrangement, a: syringe 
equipped with a needle and filled with polymer solution or melt, b: collector, c: high 
voltage power supply, d: jet ejected from the needle, e: Taylor cone 
 
Table 5 summarizes the critical parameters influencing fiber morphology including 
diameter and bead formation. These parameters can be classified as process, solution and 
ambient parameters. 
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Table 5 The most important factors influencing electrospinning (Pelipenko et al., 2013) 
Critical parameter 
Process parameter Solution parameter Ambient parameter 
applied voltage polymer molecular weight temperature 
flow rate viscosity humidity 
needle-collector distance surface tension  
needle construction solvent, solvent mixture  
collector conductivity  
 dielectric constant  
 
Beyond the basic arrangement displayed in Fig. 7, more complex apparatuses are 
available aiming at the preparation of special fiber structures or oriented fibers. The 
manufacturing of blend fibers is the more effortless, where drug and polymer are mixed 
together prior to the fiber formation. For the preparation of core-shell type fibers emulsion 
of two polymers or a specific coaxial electrospinning apparatus (equipped with a core-
shell nozzle) is required (Yarin, 2011).  
3.3.3.2. High speed rotary spinning 
Forcespinning or high speed rotary spinning has been receiving an increasing attention 
for pharmaceutical applications. The fundamental of the method is depicted in Fig. 8.  
In the course of this process, a viscoelastic polymeric solution or melt is put into a rotating 
reservoir, which has small wall orifices on its wall and is driven by a controlled engine. 
A revolution speed is achieved that is large enough to develop a centrifugal force capable 
to overcome capillary forces, thus the polymeric sample is pressed through the orifices. 
Finally, the lengthening jet will solidify upon solvent evaporation and rapid cooling. This 
method also produces continuous fibers. Beyond the driving force, one of the most 
important difference from electrospinning, that this method typically employs more 
concentrated polymeric solutions (Sarkar et al., 2010; Szabó and Zelkó, 2015).  
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Figure 8 Schematic and cutaway drawing of a spinneret applied for high speed rotary 
spinning, a: wall orifices, b: rotating reservoir, c: ejected polymeric jet or fiber, ω: angular 
velocity 
 
Angular velocity and radius of the rotating reservoir determines centrifugal force, 
according to  
 
𝐹𝐹𝑃𝑃𝑐𝑐𝑃𝑃𝐶𝐶 = 𝑚𝑚𝜔𝜔2𝑟𝑟          (7) 
 
where Fcent is the centrifugal force, m, ω and r represent the weight, angular velocity and 
radius of the rotating mass, respectively (Eq. (7)). 
 
Table 5 The most important factors influencing high speed rotary spinning (Badrossamay 
et al., 2010) 
Critical parameter 
Process parameter Solution parameter Ambient parameter 
angular velocity polymer molecular weight temperature 
radius of reservoir viscosity humidity 
diameter of orifice surface tension  
 solvent, solvent mixture  
 volatility  
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Fiber formation is in strong connection with the capillary number which is defined as 
 
𝐶𝐶𝐶𝐶 = 𝑈𝑈𝜋𝜋
𝛾𝛾
          (8) 
 
where Ca is the capillary number, η is the dynamic viscosity, γ is the surface tension and 
U is the polymer jet exit speed (Eq. (8)). It was found that above critical solution 
concentration (the concentration above which fiber formation take place) the higher the 
Ca, the better the quality of the prepared fibers and the smaller the tendency for bead 
formation (Badrossamay et al., 2010). 
3.3.4. Preparation of drug loaded micro- and nanofibers 
Preparation of drug loaded micro- and nanofibers can be carried out in several ways. The 
loading of polymeric fibers can be direct and indirect. In case of direct loading drug 
containing polymeric solutions, suspensions or melts are applied during the fiber 
formation process. In respect of indirect or active loading, neat fibers are prepared prior 
to the introduction of the active ingredient. 
The use of drug containing gels or solutions can be considered as the most convenient 
approach. However, this way of loading has some limitations: 
• the applied drug must be soluble at least in one solvent;  
• the applied solvent should be a good solvent for each component in order to avoid 
phase separation; 
• blend type fibers usually suffers from burst release; 
• potential harm of solvent residues and 
• the physicochemical stability of amorphous drug (Thakur et al., 2008; Zeng et al., 
2005b). 
The possibility to use melts is also advantageous, because of the solvent-free nature of 
the process. Nonetheless, the method is limited to thermoplastic polymers and to heat 
stable drugs. 
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Drug suspensions can be also subjected to spinning processes, but it is not a mainstream 
way of preparation drug loaded fibers. The ability of tailoring drug release through the 
modification of crystal characteristics, the thermodynamically stable nature of crystals 
are the advantages of the use of crystalline drug suspensions (Müller and Ulrich, 2012; 
Puhl et al., 2014). It must be noted, that in case of high speed rotary spinning, the formed 
centrifugal force is incompatible with drug suspensions, because of its sedimentation 
effect. 
Active loading was invented in order to address the issue of low drug loading capacity. 
In the course of this method, neat fibers prepared prior to the loading step are immersed 
in a solution of the drug, of which solvent does not dissolve the fiber forming polymer. 
Finally, the solvent will be evaporated. This proves also known as the non-solvent 
evaporation method (Kataria et al., 2014).  
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4. RESEARCH OBJECTIVES 
The general aim of the thesis was to demonstrate the importance of fiber-based 
approaches in the formulation of poorly soluble drugs and at the same time to highlight 
the prosperous possibilities hidden in high speed rotary spinning. My intention was to 
provide a comprehensive overview of the progress of a fiber-based formulation. Thus the 
thesis and its underlying experiments cover a broad spectrum of pharmaceutical 
development from the preformulation to the stability testing, therefore my aspirations 
were as follows.  
• Enrichment of the range of polymers capable for high speed rotary spinning, by 
selecting a pharmaceutical polymer, namely hydroxypropyl cellulose (HPC) for 
high speed rotary spinning that have not been reported to be rotary spun so far.  
• Conducting preformulation studies with HPCs of different average molecular 
weights in order to establish critical and optimal concentrations for fiber 
formation. The investigation of the impact of textural-rheological properties on 
fiber characteristics. 
• By means of the exploitation of HPC’s versatile solubility features (soluble both 
in water and ethanol), the preparation of drug loaded microfibers incorporating 
actives selected from BCS class II. 
• Physicochemical and supramolecular characterization of drug loaded microfibers 
with a particular attention to the crystalline-amorphous transition. 
• Formulation of a solid oral dosage form, i.e. orodispersible tablets from processed 
drug loaded microfibers for the dissolution enhancement of incorporated actives 
and for highlighting the inherent possibilities of oral administration of fibers.  
• To obtain information on physicochemical stability of drug loaded fibers using 
accelerated stability test. 
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5. MATERIALS AND METHODS 
5.1. Materials 
Klucel® EXF Pharm and ELF Pharm type HPCs were selected for fiber formation 
(Ashland, USA). The average molecular weights are 80.000 and 40.000 (based on size 
exclusion chromatography), respectively, and the moles of substitution is 3.8 for each 
polymer.  
Purified water (Ph. Eur. 8.) and the hydroalcoholic mixture of ethanol (96% v/v, Reanal, 
Hungary) and purified water (mixed in 3:1 volume ratio) were applied as solvents for the 
preparation of gels.  
Pharmaceutical grade model drug (MD) for fiber preparation was selected from BCS class 
II, and can be defined with the following physicochemical properties: Mw < 500, pKa = 
7.1 (with one basic centre), water solubility < 5.1 µg/ml, logP: 4–5. 
The other pharmaceutically active ingredient was carvedilol (CD) (EGIS Pharmaceuticals 
Plc, Hungary, Ph. Eur.) 
Citric acid monohydrate (Hungaropharma) was used for the preparation of drug stock 
solutions.  
Concentrated hydrochloric acid (Molar Chemicals, Hungary), potassium dihydrogen 
phosphate (Molar Chemicals, Hungary), sodium hydroxide (Molar Chemicals, Hungary), 
and distilled water were applied in the preparation of the dissolution media. 
The excipients of the orally disintegrating tablets were as follows: microcrystalline 
cellulose (Vivapur® 102 MCC) as filler and disintegrant, mannitol (Mannogem® EZ, SPI 
Pharma) or spray-dried lactose monohydrate (Flowlac®100, Meggle GmbH, Wasserburg, 
Germany) as filler, milled poly(ethylene glycol) 1500 (Macrogol 1500, Hungaropharma) 
or magnesium stearate (Ph.Eur. Hungaropharma, Hungary) as lubricant, equimolar 
mixture of milled citric acid anhydrate (Molar Chemicals, Hungary), and sodium 
bicarbonate (Hungaropharma) as effervescent agent and croscarmellose sodium 
(Vivasol®, JRS Pharma) as superdisintegrant agent. 
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5.2.1. Hydroxypropyl cellulose 
Hydroxypropyl cellulose is a semisynthetic derivative of cellulose, a naturally occurring 
polymer. The polymer is official in different pharmacopoeias (e.g. European 
Pharmacopoeia, United States Pharmacopoeia) and widely applied for pharmaceutical 
purposes in oral and in topical dosage forms, as well. Chemical structure of HPC is 
illustrated in Fig. 9. 
 
 
Figure 9 Chemical structure of hydroxypropyl cellulose 
 
In pharmaceutical technology, HPC is mainly used as tablet binder, film coating agent 
and extended release matrix former (Rowe et al., 2009). The polymer is freely soluble in 
water (below 38 °C) and in polar organic solvents, such as ethanol, dioxane, propanol. 
5.2.2. Carvedilol 
CD is an arylethanolamine type nonselective beta and alpha-1 adrenoreceptor blocker, 
which is used in the treatment of hypertension, coronary artery disease and congestive 
heart failure (Frishman, 1998; Morgan, 1994; Packer et al., 1996; Ruffolo and Feuerstein, 
1997).  Chemical structure of CD is represented in Figure 10. 
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Figure 10 Molecular structure of carvedilol 
 
CD exhibits poor aqueous solubility (27.11 ± 1.14 µg/mL in pH 6.8 buffer) and has a low 
oral bioavailability (below 25%), therefore it is a typical representative of BCS class II 
(v. Möllendorff et al., 1987; Zhao et al., 2011). 
 
5.2. Sample preparations 
5.2.1. Preparation of aqueous HPC gels 
Aqueous gels were prepared in a beaker by the addition of water to HPC with due regard 
to their careful homogenization. Klucel® EXF gels were prepared in the concentration 
range of 38-52 % w/w, and Klucel® ELF gels were made in the concentration range of 
42-60 % w/w with an increment of 2% w/w. In case of the former, gels were stored for 2 
hours, in case of the latter, gels were stored for 1 hour at room temperature (T=25 °C) in 
order to ensure the complete dissolution of the polymers. 
5.2.2. Preparation of drug containing HPC gels 
For MD containing gels, the drug stock solution was prepared as follows. In a 50.00 ml 
volumetric flask, 5.000 g of drug was suspended with about the half of the necessary 
amount of hydroalcoholic mixture, until a lactescent dispersion was formed. Then 3.000 
g of citric acid monohydrate (equimolar to drug) was added, and the dispersion was 
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shaken until a clear solution was formed. Finally, the solution was diluted to 50.00 ml 
with the solvent mixture. 
For CD containing gels, the drug stock solution was prepared by the following way. In a 
50.00 ml volumetric flask, 5.000 g of drug was suspended with about the half of the 
necessary amount of hydroalcoholic mixture, until a lactescent dispersion was formed. 
Then 2.590 g of citric acid monohydrate (equimolar to drug) was added, and the 
dispersion was shaken until a clear solution was formed. Finally, the solution was diluted 
to 50.00 ml with the solvent mixture. 
Drug loaded gels of 50 % w/w Klucel® ELF were prepared by the addition of the equal 
amount of drug stock solution to the amount of polymer in a beaker. After careful 
homogenization and covering with paraffin tape, the gels were let to rest at room 
temperature (T=25 °C) for 1 hour. 
5.2.3. Fiber formation 
HPC fibers were prepared via high speed rotary spinning technique. At first, the samples 
were put in a perforated aluminum rotating reservoir, which was powered by a WSE 602 
M engine (AEG, Germany). The fiber formation was carried out at 10,500 rpm. The 
rotational speed was controlled with a toroidal transformer and determined with laser 
revolution counter (DT-10L, Voltcraft, Germany). The internal diameter of the two wall 
orifices were 0.5 mm. 
5.2.4. Preparation of physical mixtures 
Following analytical assay of the drug loaded microfibers, physical mixtures of the same 
composition were made by the combination of plain drug, Klucel® ELF and citric acid. 
After sieving all components through a mesh sieve (nominal wire diameter 320 µm), the 
substances were homogenized in a Turbula (T2F model; Willey A Bachofen AG, 
Maschinenfabrik, Basel, Switzerland) at 23 rpm for 30 min in a cylindrical container. The 
mixture was used as control for the performed examinations, and for the preparation of 
control tablets. 
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5.2.5. Preparation of orodispersible tablets 
Orodispersible tablets containing 10 mg drug were prepared by direct compression 
technique using a single-punch tableting machine (Diaf TM20, Copenhagen, Denmark), 
with a shallow concave round punch of 13.5 mm. Formulas are given in Table 6, where 
microfiber based tablets were assigned as TF, and control tablets consisting physical 
mixture of hydroxypropyl cellulose, anhydrous citric acid and drug were assigned as 
TPM. After sieving all components through a mesh sieve (nominal wire diameter 320 
µm), the substances were homogenized in a Turbula (T2F model; Willey A Bachofen 
AG, Maschinenfabrik, Basel, Switzerland) at 23 rpm for 30 min in a cylindrical container. 
The batch size of 100 tablets was prepared for each composition and the tableting machine 
was powered manually. 
To ensure specified hardness (30-35 N for MD and 40-45 N for CD containing tablets) 
the applied pressures were adjusted for each formula. Final weight of MD and CD 
containing tablets was adjusted to 500 and 600 mg, respectively. 
 
Table 6 Composition of the prepared orodispersible tablets *Equimolar mixture of milled 
citric acid anhydrate and sodium bicarbonate 
 Formulation series 
Component (% w/w) MD-TF MD-TPM CD-TF CD-TPM 
Milled drug loaded microfiber (MD/CD) 20 - 11.10 - 
Vivapur® 102 28 28 30 30 
Milled poly(ethylene glycol) 1500 2 2 - - 
Magnesium stearate - - 1 1 
Vivasol® 3 3 3 3 
Effervescent agent* 7 7 5 5 
Mannogem® EZ 40 40 - - 
FlowLac® - - 49.90 49.90 
Klucel® ELF - 16.92 - 9.58 
Crystalline drug (MD/CD) - 2 - 1 
Citric acid monohydrate - 1.08 - 0.52 
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5.3. Measurements 
5.3.1. Texture analysis 
 
Figure 11 Calculation of adhesiveness from the load-displacement curve 
 
Textural measurements were carried out using Brookfield CT3 Texture Analyzer with 
4500 g load cell (Brookfield Engineering Laboratories, INC., USA) equipped with a 
cylindrical probe (TA-5, black delrin, diameter: 12.7 mm, length: 35 mm).  
The compression test comprised two cycles applying the following parameters: pretest 
speed, test speed, and return speed of 2, 1 and 1 mm/s, respectively. Trigger load was set 
to 2 g. The probe compressed the gels through a depth of 10 mm as a target distance upon 
reaching the trigger load. Brookfield Texture Pro CT software was employed for 
evaluation. The adhesiveness is given by the total negative area of the load-distance curve 
of the first cycle (Figure 11). 
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Figure 12 Measuring arrangement for adhesiveness determination with the motions of 
the probe 
 
Prior to the measurement, 10.00 g of each sample was transferred to a cylindrical glass 
container (internal diameter: 23 mm, height: 30 mm), which was fixed to the platform of 
the instrument. Three parallels of each concentration were measured.  The principles of 
the analysis is depicted in Figure 12. 
5.3.2. Percentage yield 
Percentage yield on dry polymer of the fiber formation process was calculated as follows 
(Eq. (9)): 
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𝑌𝑌𝑌𝑌𝑌𝑌𝑙𝑙𝑌𝑌 % =  𝑚𝑚𝑓𝑓𝑑𝑑𝑓𝑓𝑙𝑙𝑟𝑟
𝑚𝑚𝑔𝑔𝑙𝑙𝑠𝑠𝑃𝑃𝑎𝑎𝑝𝑝𝑠𝑠𝑝𝑝𝑙𝑙𝑙𝑙𝑟𝑟
100      (9) 
where mfiber is the weight of the fibers prepared from a gel of a weight of mgel and a 
concenctration of cpolymer. 
5.3.3. Morphological evaluation 
Fiber morphology was characterized using both optical microscopes (LCD Micro type; 
Bresser; Germany and Nikon SMZ 1000 type; Nikon, Tokyo, Japan) and scanning 
electron microscope (SEM) (Amray 1830-D4,equipped with a tungsten electron gun and 
EDAX-PV 9800 energy-dispersive spectrometer). In the course of light microscopy 
magnifications were: 40x, 100x and a standard micrometer scale was used for the 
calibration. For SEM pictures, the parameters were as follows: acceleration voltage of 15 
kV, beam current of 0.1–0.5 nA, and samples were gold coated with JEOL JEE-4B 
vacuum evaporator. Images were analyzed employing Image Pro Plus 4.5 software 
(Media Cybernetics, Bethesda, U.S.).  
5.3.4. Milling process 
Rotary knife grinder (Gorenje SMK 150 B) was applied for the particle size reduction of 
citric acid anhydrate, sodium bicarbonate, poly(ethylene glycol) 1500 and drug loaded 
microfibers. Operating parameters were as follows: milling time of 6 min, frequency of 
rotation was 24000 rpm (determined with DT-10L laser revolution counter, Voltcraft, 
Germany). All of the milled materials were sieved through a mesh sieve (nominal wire 
diameter: 320 µm). 
5.3.5. Particle size characteristics 
Information on particle size distribution was obtained by laser scattering particle size 
distribution measurement. The instrument (LA-950V2 Horiba Co., Kyoto, Japan) was 
equipped with a dry feeder unit to determine the particle diameter of the excipients and 
the milled drug loaded fibers in the range of 0.011-3000 µm. The operating parameters 
were as follows:  air pressure of 0.1 MPa; feeder intensity (0-200) was 80; and relative 
refractive index was 1.60.  
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Distribution span values were calculated to characterize the width of the distributions 
based on Eq. (10): 
 
 𝑆𝑆𝑆𝑆𝐶𝐶𝑙𝑙 = 𝐷𝐷90%−𝐷𝐷10%
𝐷𝐷50%
        (10) 
        
where D10%, D50% and D90% are the particle diameters at 10, 50 and 90% of the cumulative 
particles undersize plot. The results are the averages of five parallel measurements. 
5.3.6. UV-Vis spectroscopy 
Drug content of the milled fibers was measured by UV-vis spectroscopic assay (Agilent 
8453 UV-Vis Diode Array System, USA for MD; and Jasco 530 UV–Vis 
spectrophotometer, Japan for CD) applying 0.1 M hydrochloric acid as solvent.  The drug 
content of the samples was measured on the basis of the calibration curve recorded earlier. 
Five parallel measurements were performed. 
5.3.7. Powder X-ray diffraction (XRD) 
X’Pert Pro diffractometer (PANAnalytical, Almelo, The Netherlands) system with CuKαI 
radiation (λ = 1.5406 Å) over the interval of 2.0000 - 40.0014° was used to obtain X-ray 
diffraction patterns. The following conditions were applied: target of Cu; filter of Ni 
(thickness was 0.02 mm); voltage of 40 kV; current of 40 mA; angular step of 0.0334°; 
counting time of 40.005 s. 
5.3.8. Positron lifetime measurements 
Supramolecular characterization of samples was carried out using positron annihilation 
lifetime spectroscopy (PALS). The method exploits the relatively long lifetime of the 
unstable exotic atom, ortho-positronium (o-Ps), which is formed after a positive beta 
decay upon bounding together with an electron. o-Ps atoms tend to be trapped in the free 
volume holes of polymeric excipients, and their annihilation is not influenced by their 
intrinsic lifetime but by the electron density in the holes. Deng et al. defined how o-Ps 
lifetime is associated with the size of the free volume around them (Eq. (11))  
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𝜏𝜏3 = 12 �1 − 𝐶𝐶𝐶𝐶+∆𝐶𝐶 + 12𝜋𝜋 sin � 2𝜋𝜋𝐶𝐶𝐶𝐶+∆𝐶𝐶��−1     (11) 
where τ3 is the ortho-positronium lifetime, r the radius of the free volume hole, and Δr is 
the electron layer thickness (Deng and Jean, 1993). According to Eq. 11, the longer the 
lifetime, the larger the hole.  
For o-Ps determination carrier-free 22NaCl positron source of an activity of 105-106 Bq 
was used with a fast-fast coincidence system based on BaF2 /XP2020Q detectors and 
Ortec® electronics. Three parallel spectra were measured at each composition to increase 
reliability. After summarizing the parallels, spectra were evaluated by the RESOLUTION 
computer code (Kirkegaard et al., 1981); the indicated errors are the deviations of the 
lifetime parameters obtained. Three lifetime components were found in all the samples. 
5.3.9. Differential scanning calorimetry 
Thermograms of CD loaded microfibers were obtained using Seiko Exstar 6000/6200 
(Seiko Instruments, Japan) differential scanning calorimeter with an open aluminum pan. 
The temperature range was 6°C - 200°C and the scanning rate was set to 5°C /min under 
air atmosphere. 0.0050 g of sample was used for the measurements. 
5.3.10. Attenuated total reflectance - Fourier transform infrared (ATR-FTIR) 
spectroscopy examinations 
ATR-FTIR spectra were collected on Jasco FT/IR-4200 spectrophotometer between 4000 
and 2000 cm−1 with an ATRPRO470-H single reflection accessory (Jasco) equipped with 
flat pressure tip. The spectral measurements were performed in absorbance mode. The 
200 scans at a resolution of 2 cm−1 were co-added by the FT-IR software (Spectra 
Manager-II, Jasco). 
5.3.11. Tablet parameters 
Hardness, friability and in vitro disintegration time were determined.  
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5 tablets of each composition were measured by tablet hardness tester (8M, Dr. 
Schleuniger Pharmatron, Switzerland).  
For friability testing, ca. 6.5 g of dedusted tablets was put in an Erweka friability tester 
(TAP, Offenbach/Main, Germany). The instrument was moved for 4 min with a 
revolution speed of 25 rpm. Percentage friability was calculated by the reweighting of the 
dedusted tablets.  
In vitro disintegration times were determined applying Erweka Disintegration Tester (ZT 
4, Germany). 900 ml of demineralized water was used as the media; the measurement 
was carried out at 37±2 °C by visual observation (disk was not applied). Six tablets from 
each composition were evaluated for their disintegration times. The observed minimum 
and maximum values are reported later. 
5.3.12. Dissolution test 
Orodispersible tablets were examined in a Hanson SR8-Plus (Hanson Research, 
Chatsworth, USA) type dissolution tester equipped with rotating paddles at 37±1 °C, with 
a rotation speed of 50 rpm. Solution of hydrochloric acid of pH 1.0 (Ph. Eur. 8.), 
phosphate buffer of pH 4.5 (Ph. Eur. 8.) and phosphate buffer of pH 6.8 (Ph. Eur. 8.) were 
applied as dissolution media (the volume was 500 ml). 3.00 ml of samples were taken at 
predetermined time points using a Biohit Proline 5.00 ml pipette without refilling. The 
samples were filtered through a 10µm UHMW polyethylene cannula dissolution filter. 
The drug content of the samples was determined by UV-Vis spectroscopy (Agilent 8453 
UV-Vis Diode Array System, USA for MD, and Jasco 530 UV–Vis spectrophotometer, 
Japan for CD) at the characteristic wavelength of the drug on the basis of the calibration 
curve recorded earlier. Three parallel measurements were carried out for each sample. 
5.3.13. Comparison of the dissolution curves 
Difference (f1) and similarity (f2) factors were calculated for the mathematical 
comparison of drug release profiles. Eqs. (12) and (13) were given by Moore and Flanner 
(Moore and Flanner, 1996) and implemented by FDA CDER (Center for Drug Evaluation 
and Research): 
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𝑓𝑓1 = ∑ |𝑅𝑅𝑡𝑡−𝑅𝑅𝑡𝑡|𝑛𝑛,𝑡𝑡=1∑ 𝑅𝑅𝑡𝑡𝑛𝑛,𝑡𝑡=1 × 100        (12) 
 
𝑓𝑓2 = 50 × log� 100
�1+
∑ (𝑅𝑅𝑡𝑡−𝑇𝑇𝑡𝑡)2𝑛𝑛,𝑡𝑡=1
𝑛𝑛, �      (13) 
 
where n is the number of time points, Rt is the dissolution value of the reference sample 
at time t (compressed physical mixture), and Tt is the dissolution value of the test sample 
(microfiber based formula) at time t. Two profiles can be considered to be similar if f1 
value is close to 0, and f2 value is close to 100. Generally, f1 greater than 15, and f2 values 
smaller than 50 indicates significant difference between the dissolution of the test and 
reference product. 
5.3.14. Accelerated stability study 
Freshly prepared CD loaded microfibers were transferred into sealed snapcap vials. 
Afterwards, the samples were placed in stability chamber (Sanyo type 022, Leicestershire, 
UK) and maintained at 40 ± 2°C /75 ± 5% RH for 4 weeks. Samples subjected to stability 
test were analyzed by means of DSC, XRD, and ATR-FTIR spectroscopy and PALS. 
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6. RESULTS 
6.1. Preformulation study 
Aqueous HPC gels were simultaneously subjected to high speed rotary spinning and to 
texture analysis. The fiber formation was under optical microscopic monitoring.  
Applying Klucel® EXF gels, fiber formation was successful between the concentration 
range of 46-50 % w/w, thus the critical minimum and maximum concentrations were 46 
and 50 %w/w. Below the critical minimum concentration excessive bead formation took 
place, and above the critical maximum concentration no sample left the rotating reservoir 
under the given conditions. Figure 13 illustrate how changes of concentration influences 
morphology. The microscopic evaluation revealed that certain parts of fibers were 
helically twisted, and the phenomenon was observable at each concentration. The average 
fiber diameters are represented in Table 7. 
 
Table 7 Average diameters of the prepared fibers 
Concentration (% w/w) 
Mean diameter (µm) ± S.D. 
Klucel® EXF gels (n=50) Klucel® ELF gels (n=50) 
46 11.52±4.09 - 
48 8.93±2.17 13.5±6.1 
50 12.21±4.00 11.8±3.3 
52 - 13.0±5.0 
54 - 15.5±3.7 
 
It can be seen, that the least fiber diameter was achieved when 48% w/w gel was applied, 
moreover the standard deviation was also the smallest.  
Fig. 14 demonstrates the observed adhesiveness values and the percentage yield on dry 
polymer. The highest yield of fiber formation was obtained when applying 48% w/w gels.  
The shape of the adhesiveness curve is quite specific; at low concentrations the values are 
rising until they reach the peak, which is followed by a sharp decrease and ends in a 
plateau level. 
DOI:10.14753/SE.2016.1927
45 
 
These finding unanimously suggest that the optimal Klucel® EXF concentration for fiber 
formation is 48% w/w. 
 
Figure 13 Optical microscopic morphology of fiber formation experiments using Klucel® 
EXF gels; a: 38; b: 40; c: 42; d: 44; e: 46; f: 48; g: 50 % w/w with a helical twisted region 
enlarged 
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Figure 14 Adhesiveness values of aqueous HPC gels with the corresponding yields on 
dry substance 
 
In case of gels made of Klucel® ELF, the critical minimum concentration was 48 % w/w, 
and the critical maximum concentration was 54% w/w. In respect of 42 % w/w gels, only 
droplets were formed, while in the concentration range of 42-46 % w/w bead formation 
was dominant over fiber formation. However, at above 54 % w/w, fiber formation took 
place, the fibers were too sticky, hence they were not capable for collecting and further 
processing. The morphology of the result of the fiber formation experiment can be seen 
in Fig. 15. Helically twisted regions were also found in the prepared fibers. 
Average fiber diameters are listed in Table 6, in which the least diameter was obtained at 
50% w/w. Similarly to the previous polymer, the smallest standard deviation was also 
related to the smallest fiber diameter. The highest yield of the process was obtained when 
50% w/w gel was applied (Fig. 14). 
The adhesiveness curve is partly similar to that of Klucel® EXF, but in addition to the 
maximum point, there can be found two local minimums (at 50 and 54% w/w).  
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Figure 15 Optical microscopic morphology of fiber formation experiments using Klucel® 
ELF gels; A: 42 B: 44, C: 46, D: 48, E: 50, F: 52, G: 54, H: 56, I: 58, and J: 60 % w/w 
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Furthermore, instead of the plateau region, the adhesiveness values tend to rise again 
slightly above 54% w/w. 
The performed examinations unanimously indicate that the optimal Klucel® ELF 
concentration for fiber formation with high speed rotary spinning is 50% w/w. 
6.2. Preparation and investigation of drug loaded microfibers 
Fiber formation via high speed rotary spinning was successfully carried out by the use of 
drug containing hydroalcoholic Klucel® ELF gels, of which previously determined 
optimal polymer concentration, i.e. 50% w/w was applied. Hereinafter, the two active 
ingredient will be expounded separately.  
6.2.1. MD loaded fibers 
Morphology of MD loaded fibers is displayed in Figure 16, indicating a clear, transparent 
fibrous structure with lack of observable beads. SEM pictures imply smooth surface of 
fibers, on which drug crystals are not detectable. Mean fiber diameter was given as 
12.6±4.8 µm (n=50). The average drug content was 8.99±0.13% w/w (n=5). 
 
 
Figure 16 Optical microscopic appearance of MD loaded fibers, A: 40x, B: 100x 
magnification 
 
X-ray diffractograms revealed a change in crystallinity of the active ingredient during 
fiber formation. In X-ray pattern of physical mixture, characteristic peaks of active 
ingredient are clearly detectable, combined with diffuse peaks of the amorphous polymer. 
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In respect of XRD pattern of the fibers, these characteristic peaks are not observable (Fig. 
17). Long term ordering is a specific feature of crystalline materials, and as a result of 
this, X-rays are scattered in certain directions, which are characteristic to the substance. 
The absence of high intensity peaks implies the lack of the long term ordering, thus these 
findings indicate the crystalline amorphous transition of MD.  
 
Figure 17 XRD patterns of the investigated samples, a: MD loaded microfibers, b: 
physical mixture, c: citric acid monohydrate, d: crystalline MD 
 
PALS measurements also indicated a significant difference between fibers and the 
corresponding physical mixture. In case of the former, the decreased o-Ps lifetime, thus 
the reduction of free volume holes suggests the supramolecular ordering of the polymer 
chains (Fig. 18). It can be also associated with the formation of a SS, where amorphous 
drug is molecularly dispersed in the polymer matrix, which means that drug molecules 
wedged between the polymer chains reduce the size of free volumes. The transparent 
nature of the fibers also suggest this hypothesis (Fig. 16).  
DOI:10.14753/SE.2016.1927
50 
 
 
Figure 18 o-Ps lifetime values of investigated samples: a: physical mixture b: MD loaded 
microfibers 
6.2.2. CD loaded microfibers 
 
Figure 19 Micromorphology of CD loaded fibers: A and B: light microscopic record (40x 
and 100x magnification); C and D: SEM record (100x and 1000x magnification) 
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The microscopic morphology of fibers is represented in Fig. 19. Optical microscopic 
pictures reveal the formation of a transparent, beadless fibrous structure. Obtained SEM 
pictures provide deeper insight into fiber morphology, displaying uniform fibers of 
smooth surface. Mean fiber diameter was given as 12.1±3.5 µm (n=50). The average drug 
content was 9.01±0.26% w/w (n=5). 
The endothermic peak visible on the thermogram of the physical mixture can be related 
to the melting point of the crystalline carvedilol, which is missing from the thermogram 
of the microfibers, therefore crystalline-amorphous transition of the active ingredient 
could be concluded. 
 
 
Figure 20 DSC thermograms of investigated samples: a: CD loaded microfibers, b: 
physical mixture, c: Klucel® ELF type HPC, d: crystalline CD 
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The recorded XRD patterns also confirms the crystalline amorphous transition of CD 
(Fig. 21). Characteristic high intensity peaks originating from the crystalline CD is clearly 
detectable on the curves of physical mixture, while with respect to the diffractogram of 
fibers, only diffuse peaks can be identified. 
 
Figure 21 XRD patterns of investigated samples: a: CD loaded microfibers, b: physical 
mixture, c: Klucel® ELF type HPC, d: citric acid monohydrate, e: crystalline CD  
 
In accordance with the findings of XRD and DSC, ATR-FTIR measurements also pointed 
out the crystalline-amorphous transition of CD. The spectrum recorded from physical 
mixture bears the characteristic features of crystalline CD (-NH stretching vibration at 
3200–3300 cm−1 and -CH stretching vibrations at 2900–3100 cm−1), whils these peaks 
cannot be found in the spectrum of microfibers (Fig. 22). The observed phenomenon is 
DOI:10.14753/SE.2016.1927
53 
 
due to the lack of long term ordering specific to crystalline substances, thus enabling 
much more allowed conformations. The absorbed energy is distributed throughout the 
many conformations resulting in the merging and broadening of characteristic peaks. 
 
Figure 22 ATR-FTIR spectra of investigated samples: a: CD loaded microfibers, b: 
physical mixture, c: Klucel® ELF type HPC, d: citric acid monohydrate, e: crystalline 
CD 
 
Measurement of o-Ps lifetimes was also carried out, and the results imply a significant 
change in the supramolecular structure along with the fiber formation. The large reduction 
in o-Ps lifetime values, thus in the size of free volume holes can be related to the 
supramolecular ordering of HPC chains (Fig. 23). The reason for this can be found in the 
crystalline-amorphous transition of CD, and also in the formation of a SS. 
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Figure 23 o-Ps lifetime values of physical mixture (a) and CD loaded microfibers (b) 
6.3. Formulation and examination of orodispersible tablets 
The drug loaded microfibers were intended to be processed into orodispersible tablets. 
Therefore milling of fibers was necessary in order to obtain pharmaceutically more 
manageable samples. Along with the microfibers, citric acid monohydrate and sodium 
bicarbonate was also milled for the enhancement their disintegrating activity. 
6.3.1. MD containing orodispersible tablets 
The efficacy of the milling process was monitored by particle size measurements, of 
which results are shown in Table 8. Poly(ethylene glycol) was used as water soluble 
lubricant, because of its large particle size it was also subjected to milling. 
 
Table 8 Particle size characteristics of milled substances 
 Mean size (µm) ± S.D. Size distribution span ± S.D. 
MD loaded microfibers 208±10 2.67±0.19 
Citric acid, anhydrous 174±58 3.23±0.72 
Poly(ethylene glycol) 1500 146±12 1.44±0.14 
Sodium bicarbonate 132±1 1.78±0.01 
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Figure 24 Dissolution profiles of MD containing orodispersible tablets: A: pH 1.0, B: pH 
4.5, C: pH 6.8 (n=3) 
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Table 8 indicates that the size of milled substances are comparable to that of the size of 
common tableting excipients. 
All of the investigated tablet parameters complied with pharmacopoeial and our 
predetermined requirements, indicating that the tablets possess appropriate mechanical 
and disintegration properties (Table 9).  
 
Table 9 Tablet characteristics of MD containing orodispersible tablets 
Tablet parameter MD-TF MD-TPM 
Hardness (N) ± S.D. 32.2±1.3 32.0±1.9 
Friability (%) 0.39 0.37 
Disintegration time (s) 
25.18 
(first) 
26.72 
(last) 
25.25 
(first) 
29.31 
(last) 
Mass (g) ± S.D. 0.5008±0.0061 0.5029±0.0022 
 
The performed dissolution tests revealed a considerable difference between the examined 
formulations (Fig.24). MD release was rapid, complete and almost independent from the 
pH of the applied medium. In contrast, the pH of the medium had a great impact on the 
dissolution from the control MD-TPM tablets, resulting their incomplete drug release. 
Significant difference was confirmed by the calculated difference and similarity factors 
shown in Table 10. 
 
Table 10 Calculated difference (f1) and similarity (f2) factors 
  Test 
  MD-TF 
  f1 f2 
  pH 1.0 pH 4.5 pH 6.8 pH 1.0 pH 4.5 pH 6.8 
R
ef
er
en
ce
 MD-
TPM       
pH 1.0 11.36 15.56 11.38 45.17 44.66 50.77 
pH 4.5 123.33 88.59 97.90 17.42 24.22 22.42 
pH 6.8 323.98 258.02 275.71 10.15 14.62 13.42 
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6.3.2. CD containing orodispersible tablets 
Particle size characteristics of milled substances applied for tableting are shown in Table 
11. Based on these results we can conclude that the size of the milled materials is 
comparable to that of the common tableting excipients. In order to clarify whether fibrous 
structure could be retained after milling, SEM pictures were recorded too.  
 
Table 11 Particle size characteristics of milled substances 
 Mean size (µm) ± S.D. Size distribution span ± S.D. 
CD loaded microfibers 135±1 2.85±0.03 
Citric acid anhydrous 168±37 2.34±0.31 
Sodium bicarbonate 141±19 1.54±0.24 
 
Fig. 25 demonstrates that milling did not deteriorate the basic fibrous structure of our 
sample, moreover surface crystallization of the active was not observable either. The 
latter suggests that the chosen milling technique was suitable for the desired purpose. 
Both mechanical and disintegration properties were complied with the pharmacopoeial 
requirements, and there is no remarkable difference between CD-TF and CD-TPM in 
respect of the investigated parameters (Table 12). 
 
Table 12 Tablet characteristics of CD containing orodispersible tablets 
Tablet parameter CD-TF CD-TPM 
Hardness (N) ± S.D. 42.2±2.4 40.3±1.7 
Friability (%) 0.54 0.48 
Disintegration time (s) 
27.11 
(first) 
29.08 
(last) 
24.47 
(first) 
28.21 
(last) 
Mass (g) ± S.D. 0.5997±0.0124 0.6029±0.0102 
 
Dissolution test of CD containing tablets was carried out in two dissolution media, which 
unveiled a notable dissimilarity between release profiles. CD release from the fiber based 
tablets was very fast and complete in each dissolution media, whilst the release profile of 
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CD-TPM was firmly influenced by the employed dissolution media, resulting a deficient 
drug release at higher pH values (Fig. 26). 
 
 
Figure 25 SEM records of milled CD loaded microfibers, A: 100x, B: 500x magnification 
 
Table 13 Calculated difference (f1) and similarity (f2) factors 
   Test 
   CD-TF 
   pH 1.0 pH 6.8 
   f1 f2 f1 f2 
R
ef
er
en
ce
 CD-TPM pH 1.0 21.78 39.05 7.89 58.66 
pH 6.8 149.63 13.12 111.62 19.04 
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Figure 26 Dissolution profiles of CD containing orodispersible tablets: A: pH 1.0, B: pH 
6.8 
 
The observed difference was either corroborated by the calculated difference and 
similarity factors listed in Table 13. 
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6.4. Accelerated stability test 
Stability test under stress conditions was conducted in order to gain information on the 
physicochemical resistance of CD loaded microfibers.  
DSC analysis of the stored samples did not revealed any noteworthy change neither from 
the point of view of crystallinity, nor from the point of view of other solid state property, 
e.g. softening temperature (ca. 140–150 °C) (Fig. 27). 
 
Figure 27 DSC thermogarms of the stored CD loaded microfibers 
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XRD patterns present a more nuanced insight into physicochemical changes along with 
the storage time. Considering samples up to week 3, the drug was kept in an unchanged 
amorphous form embedded in the polymer matrix. But the diffractogram of the fiber 
stored for 4 weeks have developed slight intensity peaks resembling to that of the CD 
(Fig. 28). This suggest the partial crystallization amorphous drug. 
 
Figure 28 XRD patterns of the stored CD loaded fibers and the crystalline drug substance 
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In accordance with the findings of XRD patterns, the recorded ATR-FTIR spectra also 
indicated the partial crystallization of the active. There is no significant difference 
between the spectra up to week 3. The formation of the characteristic peak at 3200–3300 
cm−1 (-NH stretching vibration) imply the recrystallization of the incorporated CD in case 
of sample stored for four weeks (Fig. 29). 
 
Figure 29 ATR-FTIR spectra of the stored CD loaded microfibers 
 
PALS measurements were also carried out in order to monitor ageing related 
supramolecular changes. The determined o-Ps lifetime was on the rise along with the 
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storage time (Fig. 30). This can be traced back to the disturbance of the ordered 
supramolecular structure, which can be closely related to the recrystallization of CD or 
the water absorption of polymer chains. 
 
Figure 30 o-Ps lifetime of the freshly prepared and stored CD-loaded microfibers  
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7. DISCUSSION 
7.1. Preformulation study 
Suitability of HPC of different molecular weights for high speed rotary spinning was 
experimentally demonstrated. Applying concentrated aqueous HPC gels, fibers in the 
range of a few to few tens of micrometers were formed. However, recent research 
activities in the field of fiber formation focuses mainly on the preparation of nanosized 
fibers, our further goal was the preparation of fiber based oral drug delivery system 
containing milled fibers. The processing of nanosized particles is often much more 
cumbersome (e.g. homogenization with tableting excipients), than particles of a size of 
microns. The combination of microscopic analysis, monitoring of yield and texture 
analysis enabled the determination of critical minimum and maximum fiber forming 
concentrations, as well as the optimum concentration. From the point of yield it is evident 
that the higher the yield, the better the spinnability of the gel. But with respect to the fiber 
diameter and adhesiveness the observations need detailed explanations. As described 
before, high speed rotary spinning calls for viscoelastic gels, where the formed centrifugal 
force induces the lengthening of the gel jet leaving the wall orifice. Thus a better 
viscoelastic behavior results in a pronounced elongation and a consequence lower fiber 
diameter. The narrow distribution of diameters is also a desired property of the prepared 
fibers. Based on the results of image analysis, the narrowest distribution of fiber diameters 
were associated with the least mean fiber diameter. 
The designed experimental set-up for the textural characterization was intended to mimic 
this viscoelastic behavior during the fiber formation. Adhesiveness is calculated from that 
section of the load-distance curve, which is associated to the backward moving of the 
probe inserted in polymer gel. Thus the “stretching” of the viscoelastic sample could be 
correlated to the elongation in the course of the fiber formation. Based on these 
considerations it can be concluded that the lower the adhesiveness, the better the 
spinnability, since there exists a smaller inner resistance to the induced elongation. 
Another possible approach to understand the role of adhesiveness in fiber formation 
comes from the definition of the measured parameter. Adhesiveness represents the work 
necessary to overcome the attractive forces between two surfaces, it can be easily adapted 
to the applied spinning system. Therefore, adhesiveness is the work required for the 
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detachment of gels from the surface of the spinneret, in order to leave the orifices and 
form jets. Bearing all these considerations and obtained results in mind, it can be seen, 
that the lower adhesiveness values are more beneficial for high speed rotary spinning. 
The results also confirms that spinning properties are affected by not only the 
concentration, but by the average molecular weight of the polymer. A remarkable 
difference was also found between the adhesiveness values of Klucel® ELF and EXF, 
implying that the lager the molecular weight, the higher the adhesiveness. 
It has been reported previously, that HPC gels develop liquid crystalline structure which 
is affected by the polymer content of the gels (Ernst and Navard, 1989). The proposed 
structure for the aqueous gels was found to be cholesteric (Werbowyj and Gray, 1984). 
Taking all these into account it can be suggested that the specific shape of the 
adhesiveness curves is related to the concentration dependent supramolecular structure of 
HPC gels, which determines its textural properties. In other words, texture analysis 
enabled the selection of that concentration, at which a supramolecular structure beneficial 
for fiber formation is formed within the gel. 
This liquid crystalline hypothesis is in accordance with former observations published in 
literature. Canejo et al. have demonstrated that electrospinning of liquid crystalline 
solutions of cellulose derivative results in the formation of helically twisted fibers, which 
was also observable in our samples (Canejo et al., 2008). 
7.2. Preparation and investigation of drug loaded microfibers 
The results demonstrated that Klucel® ELF type HPC was a suitable polymer for the 
incorporation of active ingredients. The obtained average fiber diameters are slightly 
greater than that of presented in Table 7. The differences can be explained by the changed 
solvent and by the large amount of drug dissolved in the stock solution used for gel 
preparation. The introduction of a more volatile solvent (ethanol) into the spinning 
process, itself causes the thickening of fiber diameter. Rapid evaporation results in the 
premature solidification of ejected polymer jets leaving no room for the elongation. The 
use of a concentrated drug stock solution acts in the same way; the less solvent evaporates 
sooner. Our primary stipulation about formulation of poorly soluble drugs using the fibers 
based approach was that any kind of potential harm solvents should be avoided. Therefore 
ethanol, which has been classified as a solvent with low toxic potential (solvent class 3) 
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was applied (ICH, 2015). Both of the active ingredients are practically insoluble in water, 
and only slightly soluble in ethanol, hence ethanol alone would not be sufficient for 
dissolving them. This apparent contradiction was resolved by the exploitation of the weak 
basic centres of the drugs and the leveling effect of ethanol. Citric acid was capable to 
dissolve the actives in the presence of ethanol. Our strategy proved effective to 
circumvent low aqueous solubility without the use of harm solvents. 
The recorded microscopic images indicated the formation of a transparent system with 
lack of any signs of surface crystallization of drugs. The latter suggests that the chosen 
solvent mixture was appropriate for the spinning process- If the solvent is not a good 
solvent for one of the components, surface crystallization can take place during the 
evaporation-solidification (Zeng et al., 2005b). 
The performed physicochemical characterization unquestionably pointed out the 
crystalline-amorphous transition of the incorporated drug. However it is an interesting 
question that ASD or SS was formed. Based on the available data, we can propose that a 
SS was formed. The reason for this is could be the transparent nature of the system, and 
the great extent of o-Ps lifetime reduction (Albers et al., 2009). In SSs, amorphous drug 
is molecularly dispersed in the polymer matrix, which means that drug molecules wedged 
between the polymer chains could reduce the size of free volumes (Figure 31). 
7.3. Formulation and examination of orodispersible tablets 
The experiments were intended to highlight the importance and applicability of fibrous 
drug delivery systems in oral administration. Microfiber based tablets of appropriate 
mechanical and disintegration properties were successfully prepared by direct 
compression, a common tableting procedure. The reason for the simultaneous use of 
effervescent agent and superdisintegrant was the aim to overcome the large binding force 
exerted by HPC. 
Orodispersible tablets represent a popular dosage form, because of its several benefits, 
including the ease of administration, rapid disintegration enabling the drug absorption 
from the proximal sections of the gastrointestinal tract. The latter combined with the 
dissolution enhancing effect of fibers can result in an improved bioavailability of the drug. 
The dissolution from the fiber based formulas was rapid, complete and independent from 
the applied media in respect of each drug. This can be explained by the rapid in vitro 
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disintegration of the prepared tablets, the high specific surface area of milled fibers and 
the amorphous state of the incorporated drug. However, microenvironmental modulator 
effect of the incorporated citric acid in the drug-polymer complex could be also 
mentioned, since the dissolution of citric acid and drug form microfibers is simultaneous, 
and spatially related.  In case of the control tablets, the drug dissolution was determined 
by the pH dependent solubility features of the drugs. Since the control and fiber based 
tablets were very similar in means of tablet parameters, and had the same compositions, 
the observed differences can be exclusively associated to the microfibers.  
The results indicate that this approach can be a useful mean to improve in vitro 
performance of BCS class II drugs. Since the bioavailability of these drugs is mainly 
limited by their solubility, the rapid dissolution can result in an improved absorption. 
7.4. Accelerated stability test 
Stability is an ever critical aspect of formulation of dosage forms. Innovative, novel 
dosage forms, such as fiber based formulations are particularly watched with eager eyes. 
Amorphous state is thermodynamically not stable, therefore the stabilization of dosage 
forms containing amorphous drugs is a challenge.  
 
 
Figure 31 Proposed explanation for the supramolecular changes observed during the 
stability testing: A: raw polymer, B: freshly prepared drug loaded microfiber, C: stored 
drug loaded microfiber, D: fiber formation, E: storing 
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The performed physicochemical examinations indicated that along with the time of 
storage, the drug tended to recrystallize.  In respect of ASDs and SSs, molecular mobility 
plays a pivotal role in the stability, since a reduced molecular mobility does not allow 
amorphous molecules to aggregate and to form crystals. It has been found that molecular 
mobility can be decreased by an elevating glass transition temperature of the amorphous 
system (e.g. with the use of a polymer of a high glass transition temperature). Another 
key element of the stability of these systems is the formation of strong polymer-drug 
interactions, which keep the incorporated drug in an amorphous state (Qian et al., 2010). 
Regarding the results of the accelerated stability test, the temperature dependence of 
molecular mobility should be considered, as well (Hancock et al., 1995). The observed 
supramolecular changings along with the storage time can be interpreted as the expanding 
effect of the recrystallized drug on the polymeric chains (Figure 31).   
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8. CONCLUSIONS 
Because of their advantages in biological and in drug delivery applications, an ever 
increasing interest has been paid to polymeric fibers.  Fiber based formulations have been 
proved to be a potential approach to address the burning issue of modern pharmacy; i.e.  
poor aqueous solubility. In contrast to electrospinning, high speed rotary spinning 
represents a less charted area of fiber formation. Thus the impact of solution parameters 
on fiber formation, the processability of fibers, their applicability in the development of 
oral dosage forms, and their stability has been not fully understood in details yet. My 
work summarizes the efforts have been paid to elucidate the role of rotary spun fibers in 
pharmaceutical technology. 
Novelties and the practical relevance of my work are as follows: 
• Based on the literature review it was the first time that suitability of two different 
HPCs (Klucel® EXF and ELF) for high speed rotary spinning with the aim of 
producing polymer microfibers was demonstrated.  
• Novel experimental set-up was introduced to the preformulation studies of high 
speed rotary spinning; the method was capable to mimic the conditions 
(elongation of the viscoelastic solution) of the spinning process. Thus a 
relationship was found between adhesiveness and spinnability; the lower the 
adhesiveness the better the spinnability. The novel application of textural analysis 
was first demonstrated for the characterization of spinnability.  
• Unique shape of adhesiveness curves of the investigated HPCs was related to the 
concentration dependent liquid crystalline structure of the aqueous gels. This 
findings is in strong agreement with previous literature reports.  
• The tracking of fiber formation; the determination of critical minimum, maximum 
and the optimum fiber forming concentrations could be easily established using 
the combination of microscopic evaluation, monitoring of process yield and 
textural characterization. 
• It was the first reported that drug loaded microfibers were prepared via high speed 
rotary spinning using actives of BCS class II applying a novel approach. The high 
speed rotary spinning of polymer gels containing drugs dissolved resulted in the 
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formation of an amorphous drug delivery system and in the supramolecular 
ordering of polymer chains. 
• The fiber formation was successfully carried out without the employment of any 
harm solvent. Weak basic feature of drugs could be circumvented by the 
application of hydroalcoholic solvent mixture and citric acid. 
• It was first described that fibrous structure of drug loaded microfibers can be 
retained after milling by rotary knife grinder. 
• Novel orodispersible tablets, containing milled microfibers possessing satisfying 
features in terms of mechanical properties and in vitro disintegration were 
prepared. The combination of milled drug loaded microfibers with common 
tableting excipients enabled the preparation of orodispersible tablets by direct 
compression. 
• The novelty of the work was the pH independent (in the pH range of 1.0-6.8), 
rapid and complete drug dissolution from microfiber based orodispersible tablets. 
Explanation of these observations were the high specific surface of microfibers, 
amorphous state of active ingredient, the acidic microenvironmental modulator 
effect of citric acid in the polymer-drug complex and the rapid disintegration of 
the compressed tablets. 
• It was the first time, to the best to our knowledge, that physicochemical stability 
related data on rotary spun drug loaded microfibers was reported. 
Physicochemical stability of drug loaded microfibers is still a challenge and is 
influenced by several factors. Carvedilol loaded microfibers exhibited good stress 
tolerance capacity. Despite all of these, partial recrystallization took place by the 
end of the storage. 
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9. SUMMARY 
In this work, a rotary spun microfiber based formulation was demonstrated and discussed 
in details from the preformulation studies through tablet formulation to the stability 
testing.  
HPC, semisynthetic derivative of cellulose was selected for fiber formation, and this was 
the first time to demonstrate its spinnability via high speed rotary spinning. 
Preformulation studies of two HPCs of different average molecular weights were carried 
out by the monitoring of fiber morphology, of process yield, as well as of adhesiveness. 
In the course of texture analysis a relationship was found between spinnability and 
adhesiveness: the lower the adhesiveness, the better the spinnability. Reason for the 
specific shape of the adhesiveness curves was identified as the formation of liquid 
crystalline structure in concentrated gels of HPC. 
Drug loaded fibers were successfully manufactured employing Klucel® ELF and actives 
selected from BCS class II. Dissolution of drugs in an organic solvent, which is the 
reigning approach for preparing fibers loaded with poorly soluble drugs, was successfully 
circumvented by the application of hydroalcoholic mixture as solvent and citric acid as 
hydrotropic agent.   
Amorphous transitions of the incorporated drugs were confirmed and supramolecular 
changes of the polymeric carrier were also monitored.  
Milling of microfibers enabled the formulation of orodispersible tablets by direct 
compression. Blending milled microfibers with common tableting ingredients was 
sufficient to prepare tablets with desired mechanical and disintegration properties, which 
complied with pharmacocopeial requirements. 
The performed dissolution studies in different dissolution media of biorelevant pH values 
revealed a significant difference between fiber based and control formulations. The drug 
release of the fiber based formulations was rapid, complete and pH independent.  
Accelerated stability test indicated good stress tolerance capacity of CD loaded 
microfibers, however partial recrystallization of the drug was detectable at the last 
sampling point. 
The results widely demonstrate the applicability of polymer microfibers in the 
formulation of poorly soluble drugs. 
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9. ÖSSZEFOGLALÁS 
Értekezésemben a polimer mikroszál alapú formulációban rejlő gyógyszerészeti 
lehetőségekre szerettem volna felhívni a figyelmet. Annak érdekében, hogy a folyamatról 
átfogó képet nyújtsak az elvégzett kísérletek a preformulációs vizsgálatoktól az 
orodiszperz tabletták formulálásán át a stabilitás vizsgálatig terjednek. 
Munkám során egy, a nagy sebességű szálképzésben mindezidáig nem alkalmazott 
polimert, a hidroxi-propil-cellulózt (HPC), egy félszintetikus cellulóz származékot 
alkalmaztam. A preformulációs vizsgálatban két különböző átlagos molekulamérettel 
jellemezhető HPC-t használtam, mely a szálmorfológia, a folyamatkitermelés, és az 
előállított gélek adhezivitás értékének elemzésén alapult. A gélek állományelemzése 
során kapcsolatot találtam az adhezivitás és a szálképzési tulajdonság között, méghozzá 
minél kisebb az adhezivitás, annál kedvezőbb a szálképzési képesség.  
A Biofarmáciai Osztályozási Rendszer 2. osztályába tartozó farmakonokkal sikeresen 
állítottam elő hatóanyag tartalmú szálakat Klucel® ELF polimerből. A konvencionálisan 
alkalmazott megközelítést, azaz a vízben rosszul oldódó hatóanyag szerves oldószerben 
történő oldását sikerült megkerülni hidroalkoholos oldószerelegynek, mint nivelláló 
oldószernek és citromsavnak, mint hidrotróp oldásközvetítő anyagnak az alkalmazásával.  
A hatóanyagok kristályos-amorf átalakulását több fizikokémiai vizsgáló módszerrel is 
igazoltam, valamint a polimer hordozó szupramolekuláris szerkezetében bekövetkező 
változásokat is nyomon követtem.  
A mikroszálak őrlése lehetővé tette a gyógyszerkönyvi előírásoknak megfelelő 
mechanikai és dezintegrációs tulajdonságokkal rendelkező szájban széteső tabletták 
formulációját közvetlen préselés segítségével.  
A bioreleváns kémhatású kioldó közegben végzett kioldódás vizsgálatok szignifikáns 
különbséget jeleztek a szál alapú és a kontroll tabletták kioldódása között. A mikroszál 
alapú tabletták esetén a kioldódás gyors, teljes és pH független volt, szemben a kontroll 
tabletták kioldódásával.  
A gyorsított stabilitásvizsgálat során a mikroszálaknak jó stressz tűrő kapacitása volt, 
ugyanakkor az utolsó mintavételi pontnál a hatóanyag részleges kikristályosodására utaló 
jelek is megfigyelhetőek voltak. 
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